



Regeneron President and CEO Leonard S. Schleifer Named Ernst & Young Entrepreneur Of The Year® 2011 New York Award Winner

June 13, 2011

Regeneron President and CEO Leonard S. Schleifer Named Ernst & Young Entrepreneur Of The Year® 2011 New York Award Winner

Tarrytown, New York, June 13, 2011 - Regeneron Pharmaceuticals, Inc. (NASDAQ: **REGN**) today announced that its president and chief executive officer, Leonard S. Schleifer, M.D., Ph.D., received the Ernst & Young Entrepreneur Of The Year® 2011 New York Award in the healthcare services category. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Dr. Schleifer, who founded Regeneron in 1988, was selected by an independent panel of judges, and the award was presented June 8th at a dinner at the New York Marriott Marquis Hotel.

Regeneron is the largest independent biotechnology company based in New York State, with about 1,500 employees, one marketed drug, and 11 drug candidates in clinical development.

"This honor is a tribute to the dedicated men and women at Regeneron who have worked with great commitment and creativity to build our company into one of the leading firms in the biotechnology industry," said Dr. Schleifer. "From the day we opened our labs in Westchester County more than two decades ago, and under the scientific leadership of our Chief Scientific Officer, Dr. George Yancopoulos, our mission has been to apply rigorous science to discover and develop new drugs for patients suffering from serious diseases. We are proud that today we have one approved product, ARCALYST® (rilonacept) for a rare genetic inflammatory disease, a second product, VEGF Trap-Eye, which is under review by the U.S. Food and Drug Administration for the treatment of wet age-related macular degeneration, the number one cause of vision loss in the elderly, and many other drug candidates being tested in a variety of serious medical conditions."

As a New York award winner, Dr. Schleifer is now eligible for consideration for the Ernst & Young Entrepreneur Of The Year 2011 National Award. Award winners in several national categories, as well as the overall Ernst & Young Entrepreneur Of The Year National Award winner, will be announced at the annual awards gala in Palm Springs, California, on November 12, 2011.

The Ernst & Young Entrepreneur Of The Year Awards Program celebrates its 25th anniversary this year. Past award winners have included Howard Schultz of Starbucks Coffee Company, Arthur M. Blank of AMB Group, LLC (Home Depot, Atlanta Falcons), Pierre Omidyar of eBay, Inc., Ruth Fertel of Ruth's Chris Steak House, Inc., Maxine Clark of Build-a-Bear Workshop, Tom Adams of Rosetta Stone Inc., Matt Szulik of Red Hat, Inc., and last year's national winner, Howard Lutnick, Chairman and CEO of Cantor Fitzgerald and BGC Capital Partners, Inc.

About Ernst & Young Entrepreneur Of The Year®

The Ernst & Young Entrepreneur Of The Year® award encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 140 cities in more than 50 countries.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Media Contact at Regeneron:

Laura Lindsay, 914.345.7678
laura.lindsay@regeneron.com

Media Contact at Ernst & Young

Michelle Mucci Liotta, 212-773-0975
Michelle.liotta@ey.com